Fig. 5: In vivo xenograft tumor suppression by CD30 CAR T cells. | Cancer Gene Therapy

Fig. 5: In vivo xenograft tumor suppression by CD30 CAR T cells.

From: A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb

Fig. 5

A The average tumor dimensions were monitor after intravenously injected with CD30 CAR T cells, NC CAR T cells, or saline at the day of 1 (arrow show, **p < 0.01 vs. saline), B the imaging of tumor tissue treated with CD30 CAR T (bottom line), NC CAR T (middle line), and saline (up to line) at 30 days, C the tumor weight at 30 days, **p < 0.01 vs. saline, D the survival rate of xenograft tumor-bearing mice, **p < 0.01 vs. saline, immunohistochemical analysis of cytokine levels in tumor sections at day 30, GM-CSF (E), TNF-α (F), and INF-γ (G) expression in tumors is shown as percentages of positive area.

Back to article page